With the prospect that innovative drug therapies will be introduced in the coming years, society demands new approaches and concepts for comparative risk/benefit evaluation. Those evaluations will be carried out once these therapies have been used widely in daily practice. Comparisons of the risk and benefit of different drug therapies will be done in the framework of observational epidemiological studies (proof of 'safety', proof of 'effectiveness'). This is the logical next step after randomized clinical trials, which are designed to provide evidence of a drug's 'efficacy'.
Pharmacoepidemiology and Clinical Pharmacology
Phone : +31 (0)30 253 7324
Fax : +31 (0)30 253 9166
19 September 2017
The Royal Holland Society of Sciences and Humanities (KHMW) has announced that the Saal van Zwanenberg Honorary Award 2017 is awarded to Prof. Jan Schellens,
31 May 2016
MyWorkplace has recently been extended to include a research environment for the Department of Pharmaceutical Sciences.
8 December 2015
A European project for research into difficult-to-treat childhood asthma has been honoured with a grant of almost € 1 million
30 October 2017 16:15 - 17:15
PhD defence of Mette Heringa
29 November 2017 14:30 - 15:30
PhD Defence: Clinical Pharmacology of Kinase Inhibitors in Oncology: Optimized & Personalized Dosing
PhD defence of Remy Verheijen